Literature DB >> 16630533

Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes.

Jørgen de Jonge1, Pieter Schoen, Wouter ter Veer, Toon Stegmann, Jan Wilschut, Anke Huckriede.   

Abstract

Virosomes are reconstituted viral envelopes that can serve as vaccines and as vehicles for cellular delivery of various macromolecules. To further advance the use of virosomes, we developed a novel dialysis procedure for the reconstitution of influenza virus membranes that is easily applicable to industrial production and compatible with encapsulation of a variety of compounds. This procedure relies on the use of 1,2-dicaproyl-sn-glycero-3-phosphocholine (DCPC) as a solubilizing agent. DCPC is a short-chain lecithin with detergent-like properties and with a critical micelle concentration of 14 mM. DCPC effectively dissolved the influenza virus membranes after which the nucleocapsids could be removed by ultracentrifugation. The solubilized membrane components were reconstituted either by removal of DCPC by dialysis or by a procedure involving initial dilution of the solubilized membrane components followed by dialysis. Both protocols resulted in removal of 99.9% of DCPC and simultaneous formation of virosomes. Analysis of the virosome preparations by equilibrium sucrose density gradient centrifugation revealed co-migration of phospholipid and protein for virosomes produced by either method. Moreover, both virosome preparations showed morphological and fusogenic characteristics similar to native influenza virus. Size, homogeneity and spike density of the virosomes varied with the two different reconstitution procedures employed. The recovery of viral membrane proteins and phospholipids in the virosomes was found to be higher for the dilution/dialysis procedure than for the simple dialysis protocol. This novel procedure for the production of virosomes is straightforward and robust and allows further exploitation of virosomes as vaccines or as drug delivery vehicles not only in academia, but also in industrial settings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630533     DOI: 10.1016/j.bbamem.2006.03.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Novel antigen delivery systems.

Authors:  Maria Trovato; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2015-08-12

2.  Reconstruction of H3N2 influenza virus based virosome in-vitro.

Authors:  Asghar Abdoli; Hoorieh Soleimanjahi; Masoumeh Tavassoti Kheiri; Abbas Jamali; Hesam Sohani; Mohsen Abdoli; Hamid Reza Rahmatollahi
Journal:  Iran J Microbiol       Date:  2013-06

3.  Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA.

Authors:  Jørgen de Jonge; Johanna M Leenhouts; Marijke Holtrop; Pieter Schoen; Peter Scherrer; Pieter R Cullis; Jan Wilschut; Anke Huckriede
Journal:  Biochem J       Date:  2007-07-01       Impact factor: 3.857

Review 4.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

5.  Solid bioneedle-delivered influenza vaccines are highly thermostable and induce both humoral and cellular immune responses.

Authors:  Peter C Soema; Geert-Jan Willems; Klaas van Twillert; Gijsbert van de Wijdeven; Claire J Boog; Gideon F A Kersten; Jean-Pierre Amorij
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

6.  Inactivation of human and avian influenza viruses by potassium oleate of natural soap component through exothermic interaction.

Authors:  Takayoshi Kawahara; Isamu Akiba; Megumi Sakou; Takemasa Sakaguchi; Hatsumi Taniguchi
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

7.  Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability.

Authors:  J Lederhofer; J van Lent; F Bhoelan; Z Karneva; A de Haan; J C Wilschut; T Stegmann
Journal:  Pharm Res       Date:  2018-07-03       Impact factor: 4.200

Review 8.  Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?

Authors:  Babak Jalilian; Stig Hill Christiansen; Halldór Bjarki Einarsson; Mehdi Rasoli Pirozyan; Eskild Petersen; Thomas Vorup-Jensen
Journal:  Mol Cell Ther       Date:  2013-11-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.